Biolinq Shine Review: Needle-Free Glucose Sensor, Price, FDA Status

A glucose patch that reads the top layers of your skin, with no insertion needle, now has FDA authorization. Here is what it shows, what it has not yet proven, and who should wait for the missing details.

For most people who wear a continuous glucose monitor, the experience begins the same way: an applicator pressed against the arm, a click, and a thin sensor seated beneath the skin in the tissue where it will stay for a week or two. The Biolinq Shine, made by the San Diego company Biolinq, is built to skip the needle in that moment. It is a wearable patch whose sensing elements reach only into the upper layers of the skin, and on September 23, 2025, the FDA granted it a De Novo classification (DEN240080), the pathway for novel devices with no existing equivalent on the market. Biolinq bills it as the first fully autonomous, needle-free glucose sensor.

The idea is older than the product. In 2005, a Georgia Tech team pressed glass microneedles with tip radii of 15 to 40 micrometers into human skin, drew out a few microliters of the fluid that bathes the dermis, and found that its glucose tracked fingerstick values; the volunteers generally described the procedure as painless (Diabetes Technology and Therapeutics, 2005). Twenty years separate that bench experiment from a device a regulator would authorize. The gap was never the physiology. It was engineering a sensor that could live in skin for days and still be right.

The Shine is a genuine first, and it arrives with an unusual set of blanks. As of October 2026, PubMed indexes no peer-reviewed accuracy study of it, and as of November 2026 Biolinq has not published a retail price. On September 24, 2026, Biolinq announced a second FDA milestone: a 510(k) clearance for over-the-counter use in adults 22 and older who do not use insulin. You still cannot buy it off a shelf: it is sold by prescription now, with over-the-counter sales expected in early 2027. This review separates what is documented from what is still a press release.

What Is the Biolinq Shine?

The Biolinq Shine is a wearable glucose sensor made by Biolinq that measures glucose in the upper layers of the skin rather than in the tissue beneath it, and that communicates glucose ranges through a color-coded signal instead of a number you must look up. The FDA authorized it through the De Novo pathway in September 2025 and cleared it for over-the-counter use in September 2026.

The documented outline is clear even where the fine print is not. Trade coverage of the FDA decision describes an intradermal glucose sensor, a sensor patch that signals glucose ranges by color, and a multi-analyte wearable that also tracks activity and sleep. Biolinq’s own description, “fully autonomous,” signals a patch meant to work on the body without a phone for every glance. Its first-in-human feasibility results, announced before the FDA decision, described continuous glucose monitoring in the dermis. A 2026 scoping review of glucose monitoring technologies in the Journal of Materials Chemistry B placed the Shine in a category of its own among representative commercial systems: shallow intradermal arrays, listed alongside Dexcom, FreeStyle Libre, and the implanted Eversense.

Biolinq is not a garage project. The company announced a $100 million financing in November 2021 that unveiled its micro-sensing technology in the skin, a $58 million raise in April 2024 to carry its wearable biosensor through a pivotal trial, and the close of a $100 million Series C in April 2025, more than $250 million across those three rounds. Its scientific roots run through academic microneedle research: a 2017 paper in Biosensors and Bioelectronics, co-authored by a Biolinq scientist with the University of California, San Diego laboratory of Joseph Wang, described a skin-worn microneedle sensor array that measured alcohol electrochemically, tested in artificial interstitial fluid and mouse skin. The Shine itself made TIME’s list of the Best Inventions of 2026.

What we could not confirm matters as much. Older versions of this page, and much of the internet, repeat specific claims about wear time, body location, the exact colors, and how much shallower the sensor sits than a conventional CGM. We could not verify those details from the FDA, Biolinq, or a major outlet in this review, so they are not here. When Biolinq publishes its labeling and user guide, they belong in the record.

How Does the Biolinq Shine Work?

Glucose leaves the bloodstream through the walls of tiny capillaries and bathes the surrounding cells in interstitial fluid. The Shine places very shallow sensing elements into that fluid in the dermis, measures the local glucose level, and translates the result into a color-coded range signal. Conventional CGMs read the same kind of fluid, but deeper, in the tissue beneath the skin.

Picture skin as a three-story building. The top floor, the epidermis, is a roof of flattened, mostly dead cells whose job is to keep the world out. The middle floor, the dermis, is the working level: a mesh of collagen threaded with capillary loops and nerve endings, flooded with interstitial fluid that carries glucose from the blood to every cell. The ground floor is the subcutaneous fat. A standard CGM filament is placed into that lower level. The Shine’s premise is that the middle floor holds the same information, closer to the surface, which is why a sensor can work shallow enough to need no insertion needle.

Glucose reaches that fluid on a delay. After a meal, sugar rises in the blood first, then diffuses outward through capillary walls, so every interstitial sensor reads the recent past. A 2026 review in the Journal of Materials Science: Materials in Medicine put that diffusion lag at 5 to 10 minutes, with interstitial glucose correlating tightly with blood glucose in clinically validated systems. In the first independent evaluation of over-the-counter CGMs, a 2026 study of 39 young adults without diabetes, cross-correlation estimated a population lag of 6.2 minutes (Journal of Diabetes Science and Technology, 2026). For a range display, a few minutes rarely matter. For a falling glucose in someone on insulin, they can.

Most wearable glucose sensors turn glucose into current through chemistry: an enzyme reacts with glucose at an electrode, and the reaction produces a measurable electrical signal. A 2025 review of interfering substances in the Journal of Diabetes Science and Technology classified commercial CGMs by that measurement principle and noted that electrochemical designs can be thrown off by other electroactive compounds or by anything that disrupts the enzyme. Biolinq has not published the Shine’s sensor chemistry in a peer-reviewed paper we could find, though its scientists’ earlier academic work used enzyme electrodes built into microneedles. The company has also registered a study on external interferents (NCT06560177), which suggests it is testing exactly this vulnerability.

The final step is the most consequential design choice. Rather than a number, the Shine signals glucose ranges by color. The international consensus on CGM targets defines the standard target range as 70 to 180 mg/dL and recommends that adults with type 1 or type 2 diabetes spend more than 70 percent of readings, more than 16 hours and 48 minutes a day, inside it, with less than 4 percent below 70 mg/dL (Diabetes Care, 2019). We could not confirm which thresholds the Shine’s colors use or whether the companion app also shows numeric values. That is the first question to answer before you buy.

How Accurate Is the Biolinq Shine? What the Research Shows

Nobody outside Biolinq and the FDA can say precisely yet. As of October 2026, PubMed indexes no peer-reviewed accuracy study of the Shine. The De Novo decision rests on data the agency reviewed, and Biolinq presented results at the 2026 American Diabetes Association meeting, but independent, published performance numbers for the device are not yet available.

What the regulator saw. The FDA’s De Novo decision summary for DEN240080 is public, and it is the most authoritative description of what was tested. A De Novo grant means the agency found that general and special controls can provide reasonable assurance of safety and effectiveness for the device’s labeled use. It does not tell you how often the Shine’s color agrees with a lab glucose analyzer. That is what a peer-reviewed paper would show.

The yardsticks it will be measured against. CGM accuracy is usually reported as MARD, the mean absolute relative difference between sensor readings and a reference analyzer; lower is better. In Dexcom’s pivotal study of its G7, 316 adults wearing 619 sensors produced 77,774 matched readings, with a MARD of 8.2 percent on the arm and 9.1 percent on the abdomen (Diabetes Technology and Therapeutics, 2022). In Abbott’s study of the FreeStyle Libre 3, data from 100 participants showed a MARD of 7.8 percent, with 93.4 percent of readings within 20 percent or 20 mg/dL of the reference (Diabetes Therapy, 2023). Both studies were run with manufacturer scientists among the authors, which is normal for pivotal device work and worth knowing.

What happens outside the pivotal trial. The 2026 independent study of over-the-counter CGMs in 39 young adults without diabetes is the most useful caution in the literature. Overall MARD against a capillary meter was 12.9 percent, only 66.5 percent of readings fell within 15 percent or 15 mg/dL, agreement worsened after a sugary drink (MARD 15.3 percent versus 10.6 percent after placebo), and 13.8 percent of trend arrows were classified as moderate to extreme risk (Journal of Diabetes Science and Technology, 2026). The authors concluded that these devices track overall trends reasonably well but are less reliable for exact values. That study did not test the Shine. It does show that real-world performance can drift from launch numbers, and that the moments people care about most, right after eating, are the hardest to measure.

The question a color display raises. A range signal changes what accuracy means. The relevant number is not only how close the sensor is to the true value, but how often it puts you in the right color. A sensor can carry a respectable MARD and still flip categories when your glucose hovers near a threshold, such as 180 mg/dL after lunch. Ask for category agreement data, ideally the percentage of time the Shine’s range matches a reference analyzer’s range, when Biolinq or independent researchers publish.

Does glucose feedback help at all without insulin? This is where the evidence is stronger, though it comes from other devices. The IMMEDIATE randomized trial enrolled 116 adults with type 2 diabetes on non-insulin medications and an HbA1c of 7.5 percent or higher (mean age 58). After 16 weeks, those given a flash glucose monitor plus diabetes education spent 9.9 percentage points more time in range, about 2.4 hours a day, and lowered HbA1c by 0.3 percentage points more than education alone, with higher satisfaction (Diabetes, Obesity and Metabolism, 2023). For scale, the international consensus notes that each 10 percent increase in time in range has corresponded to roughly a 0.5 percentage point drop in HbA1c in pooled type 1 diabetes trial data. A 2026 review in Current Diabetes Reports concluded that CGM use in type 2 diabetes is associated with consistent improvements in HbA1c and time in range across insulin and non-insulin regimens, while a 2026 review in Cureus cautioned that the evidence is stronger for glycemic metrics than for long-term outcomes. None of that was tested with a color-only interface. Whether glanceable ranges drive the same behavior change as numbers and graphs is a reasonable hypothesis, not a finding.

For a framework on reading claims like these, our explainer on what “clinically validated” actually means is a useful companion.

What the Biolinq Shine Gets Right

The Shine gets the most stubborn barrier in glucose monitoring right: it removes the insertion needle. Its other strengths, glanceable feedback, a clean regulatory path, and a serious company behind it, all serve that one idea of making glucose awareness easier to start and easier to keep.

It attacks the reason people say no. Fear of needles is a well-documented drag on diabetes care; a 2026 review in Life listed injection pain and needle fear among the physical and psychological barriers that delay insulin and undermine adherence. A glucose sensor that does not use an insertion needle removes the moment many people dread. If that converts reluctant non-users into people who look at their glucose every day, the public health value could exceed any accuracy decimal.

It meets people where their attention is. Most CGMs speak in numbers, arrows, and graphs, and they assume you will open an app to interpret them. A color on the body asks for less. For someone who wants to know whether lunch pushed them high, not by how many milligrams, a range signal may be the right amount of information.

It earned a new regulatory category, then a broader one. The De Novo pathway exists for devices that do not fit an existing type, and the Shine went through it rather than borrowing a predicate. A year later, Biolinq announced a 510(k) clearance for over-the-counter use. Two FDA decisions about a year apart is a meaningful signal of regulatory confidence, even if the details behind them deserve publication.

It looks beyond glucose. Coverage of the FDA decision described the Shine as a multi-analyte wearable that tracks activity and sleep alongside glucose. Putting those signals on one patch makes it easier to see how a short night or a long walk shows up in the next day’s glucose.

Where the Biolinq Shine Falls Short

The Shine’s shortcomings are mostly gaps in the public record: no peer-reviewed accuracy data, no published price, and no retail availability until early 2027. It is also a range display, which limits what it can safely be used for, and “needle-free” describes the experience more than the anatomy.

The evidence is not yet public. A device authorized in 2025 and cleared for over-the-counter use in 2026 should be able to point to a peer-reviewed accuracy study by now, or soon. Until one appears, every claim about how well the Shine reads glucose rests on the company’s presentations and the FDA’s summary. That is not nothing. It is also not the independent replication that should precede a confident recommendation.

“Needle-free” is a precise word, not a synonym for non-invasive. The Shine does not draw glucose through intact skin by light or radio waves. Its sensing elements enter the upper skin layers, which is why the 2026 Journal of Materials Chemistry B review classified it as a shallow intradermal array within minimally invasive monitoring. The distinction matters because truly needle-free methods remain early: a 2022 pilot of a magnetohydrodynamic technique that pulled interstitial fluid out without needles tested 5 healthy volunteers and reached a MARD of 12.9 percent only after calibration and lag correction (Scientific Reports, 2022). The Shine is further along than that. It is still in the skin.

Ranges are not doses. A color tells you which side of a line you are on. People who calculate insulin from sensor readings need values, trend rates, and alerts from a system cleared for that purpose. Nothing in the public record we found suggests the Shine is meant for insulin dosing, and a range display cannot support it.

The label is narrow. The over-the-counter clearance covers adults 22 and older who do not use insulin. Biolinq describes the Shine as providing glucose range information for general awareness of patterns and trends, not for medical decisions such as insulin dosing or medication changes. If you take insulin or a sulfonylurea, talk to your clinician first.

You cannot buy it off the shelf yet. Trade coverage reported that Biolinq aimed for a US debut in early 2026. As of November 2026 the Shine is available by prescription, over-the-counter sales are expected in early 2027, and Biolinq has not published a retail price or subscription structure. A device you cannot price is a device you cannot yet compare.

It cannot diagnose you. Over-the-counter glucose sensors invite self-screening, and the evidence does not support it. A 2026 commentary in Diabetes Technology and Therapeutics concluded that CGM is not ready to diagnose prediabetes; in one study it cited, the best-performing CGM threshold reached 88 percent specificity but only 48 percent sensitivity. If you are worried about diabetes, an HbA1c test from your clinician is the answer.

Biolinq Shine vs Dexcom Stelo vs FreeStyle Libre 3

The Shine trades numbers for simplicity and an insertion needle for a shallow intradermal array. Dexcom Stelo is the established over-the-counter option that shows glucose values in a phone app. FreeStyle Libre 3, now being replaced by Libre 3 Plus, is a prescription CGM with published accuracy data. Your choice depends on whether you need numbers, a prescription, or simply a nudge.

Feature	Biolinq Shine	Dexcom Stelo	FreeStyle Libre 3 (moving to 3 Plus)
Where it reads glucose	Upper skin layers (shallow intradermal array)	Interstitial fluid beneath the skin	Interstitial fluid beneath the skin
What you see	Color-coded glucose ranges; numeric app values not confirmed	Glucose readings through a smartphone app	Glucose readings and trends
Prescription needed	No, per the September 2026 over-the-counter clearance	No; FDA’s first over-the-counter CGM (2024)	Yes
Peer-reviewed accuracy data	None indexed in PubMed as of October 2026	No Stelo-specific study found in PubMed	MARD 7.8% in 100 participants (Abbott-led, 2023)
Best for	Needle-averse adults who want glanceable range feedback	People not on insulin who want numbers without a prescription	People whose clinician wants precise values and trends

The Dexcom Stelo is the natural rival. The FDA cleared it in 2024 as the first over-the-counter CGM, and a 2025 review in the Journal of Pharmacy Practice noted that the first over-the-counter glucose biosensors, available that year, were aimed at people with diabetes who do not use insulin and at healthy adults tracking their health. Stelo runs through a smartphone; a 2026 study protocol using it in prediabetes required participants to have a compatible phone. If you want to see the actual number after a bowl of oatmeal, Stelo answers a question the Shine, as far as we can confirm, does not.

The FreeStyle Libre 3 represents the prescription standard, and Abbott now directs users to transition to the FreeStyle Libre 3 Plus. Prescription systems such as the Libre line and the Dexcom G7 are the right tools for anyone using insulin, because they deliver values and trends with published single-digit MARDs. If you want to see every metabolic tool we cover, browse our nutrition and metabolic health device reviews.

Where to Buy the Biolinq Shine

As of November 2026, the Biolinq Shine is not on store shelves. The FDA cleared it for over-the-counter sale on September 24, 2026, but TIME’s Best Inventions of 2026 listing reports that it is currently available by prescription, with over-the-counter availability expected early next year. That points to retail and online sales in early 2027.

Until then, the route is a prescription. Ask your primary care clinician or an endocrinologist whether it suits you; the label covers adults 22 and older who do not use insulin. When over-the-counter sales open, buy from Biolinq or a retailer it names rather than a third-party reseller, and check whether app features cost extra.

If you want a glucose sensor without a prescription today, two are already sold over the counter: the Dexcom Stelo and the Abbott Lingo. Both use a small applicator that places a thin filament under the skin, and both show readings in a phone app instead of a light on the patch.

How Much Does the Biolinq Shine Cost, and Is It Covered or HSA/FSA Eligible?

As of November 2026, Biolinq has not published a price for the Shine: no retail price, per-sensor cost, or subscription fee that we could verify from the company, the FDA, or a major outlet. Over-the-counter sales are expected in early 2027, so watch for a price closer to then. Insurance coverage and HSA or FSA eligibility are likewise unconfirmed.

When a price appears, compare cost per day of monitoring, not per box, because wear time per patch determines what a month costs. Ask whether app features carry a subscription and where the over-the-counter version is sold. If your plan covers a prescription CGM, a covered device may cost you less than any over-the-counter option.

Coverage for over-the-counter glucose sensors is still being worked out. A 2026 review in Current Diabetes Reports found CGM to be cost-effective in type 2 diabetes but documented persistent gaps in uptake by insurance coverage and care setting, and it called specifically for evaluation of over-the-counter CGM. For HSA and FSA reimbursement, ask your plan administrator before you buy; we could not confirm Biolinq’s position.

Who Should Use the Biolinq Shine, and Who Should Skip It?

The Shine suits adults who have stayed away from glucose monitoring because of the insertion needle and who want simple, glanceable feedback on how food, movement, and sleep affect them. It is the wrong tool for insulin dosing, for diagnosing yourself, and for anyone who wants the precise numbers and trend data a conventional CGM provides.

Reasonable candidates (the label covers adults 22 and older who do not use insulin):

• Adults with type 2 diabetes managed without insulin who have refused or abandoned conventional CGMs because of insertion anxiety.
• People who find CGM graphs overwhelming and would rather know, at a glance, whether they are in range.
• Early adopters comfortable paying for a first-generation device whose independent accuracy data are still to come.

Better served by something else:

• Anyone on insulin, or on medications that can cause low blood sugar: use a prescription CGM your clinician selects.
• Anyone with type 1 diabetes: the public record we found does not support using the Shine for type 1 management.
• People who want exact numbers and graphs without a prescription: an over-the-counter CGM such as Stelo shows values.
• Anyone hoping to find out whether they have diabetes or prediabetes: get an HbA1c test.

If you need an endocrinologist or diabetes specialist to help choose a monitor, the Healthcare Discovery doctor directory lists clinicians by state and specialty.

What This Means for You

Metabolic dysfunction is the Energy Arsonist in Healthcare Discovery’s framework of the Four Villains of Health and Longevity: a slow fire that starts with glucose spikes and insulin resistance and spreads into the arteries, where it feeds the Silent Assassin, cardiovascular disease. Most of that damage happens years before a diagnosis, during a long stretch when nobody is measuring. A device that makes measuring easier to start is aimed at exactly that window.

But a sensor is a mirror, not a medicine. The evidence that glucose feedback helps, from the IMMEDIATE trial’s 2.4 extra hours a day in range to the broader reviews of CGM in type 2 diabetes, is evidence that people change what they do when they can see the consequences. The Five Pillars are where that change happens. Nutrition is the obvious lever: the order and composition of a meal shape the curve that follows it. Movement is the underrated one, because working muscle pulls glucose out of the blood. Sleep is the hidden one, and a patch that tracks glucose, activity, and sleep together lets you check, in your own data, whether short nights show up in the next day’s glucose.

The honest verdict is patience. The Shine may turn out to be the device that finally makes glucose awareness as ordinary as a step count. It may also turn out to be a first-generation sensor whose colors are right most of the time and wrong at the moments that matter. As of October 2026, the public record cannot tell those futures apart. When Biolinq publishes its price and a peer-reviewed accuracy study, we will update this review. Until then, the best glucose monitor is the one you will actually wear, and for many people that is already on a pharmacy shelf.

Frequently Asked Questions

Sources

1. U.S. Food and Drug Administration. De Novo classification DEN240080, Biolinq Incorporated, granted September 23, 2025. FDA database; decision summary
2. Biolinq. Biolinq Shine granted De Novo classification by U.S. FDA for the first fully autonomous, needle-free glucose sensor (company announcement), September 25, 2025. GlobeNewswire
3. Biolinq. Biolinq Shine receives FDA 510(k) clearance for over-the-counter use (company announcement), September 24, 2026. GlobeNewswire
4. Biolinq. Biolinq announces close of $100M Series C financing (company announcement), April 2025. Business Wire
5. Biolinq External Interferent Protocol. ClinicalTrials.gov NCT06560177. ClinicalTrials.gov
6. Wang PM, Cornwell M, Prausnitz MR. Minimally invasive extraction of dermal interstitial fluid for glucose monitoring using microneedles. Diabetes Technology and Therapeutics, 2005. DOI
7. Mohan AMV, Windmiller JR, et al. Continuous minimally-invasive alcohol monitoring using microneedle sensor arrays. Biosensors and Bioelectronics, 2017. DOI
8. Wang W, et al. Toward continuous and non-invasive monitoring: a scoping review of blood glucose devices. Journal of Materials Chemistry B, 2026. DOI
9. Sodeify R, et al. Nanostructured electrode materials and flexible-substrate engineering for wearable multi-analyte biosensors in diabetes monitoring. Journal of Materials Science: Materials in Medicine, 2026. DOI
10. Setford SJ. The impact of interfering substances on continuous glucose monitors, part 1. Journal of Diabetes Science and Technology, 2025. DOI
11. Battelino T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care, 2019. DOI
12. Garg SK, et al. Accuracy and safety of Dexcom G7 continuous glucose monitoring in adults with diabetes. Diabetes Technology and Therapeutics, 2022. DOI
13. Alva S, et al. Accuracy of the third generation of a 14-day continuous glucose monitoring system. Diabetes Therapy, 2023. DOI
14. Prakash N, et al. Agreement of over-the-counter continuous glucose monitors with capillary-meter glucose in young adults without diabetes. Journal of Diabetes Science and Technology, 2026. DOI
15. Aronson R, et al. Impact of flash glucose monitoring in people with type 2 diabetes inadequately controlled with non-insulin antihyperglycaemic therapy (IMMEDIATE). Diabetes, Obesity and Metabolism, 2023. DOI
16. Perini Villanueva G, et al. Continuous glucose monitoring in type 2 diabetes: clinical outcomes, disparities in access, and cost-effectiveness. Current Diabetes Reports, 2026. DOI
17. Bazan A, et al. Continuous glucose monitoring beyond intensive insulin therapy in type 2 diabetes. Cureus, 2026. DOI
18. García-Sáenz M, et al. Advances in insulin delivery: transdermal and needle-free technologies. Life, 2026. DOI
19. Hakala TA, et al. Pilot study in human healthy volunteers on the use of magnetohydrodynamics in needle-free continuous glucose monitoring. Scientific Reports, 2022. DOI
20. DeVries JH. Continuous glucose monitoring is not ready for the diagnosis of prediabetes. Diabetes Technology and Therapeutics, 2026. DOI
21. Arriazola J, et al. Review of over the counter and prescription continuous glucose monitoring. Journal of Pharmacy Practice, 2025. DOI
22. Cowart K, et al. Pharmacist-led continuous glucose monitoring for prediabetes: protocol for a prospective cohort study. JMIR Research Protocols, 2026. DOI
23. U.S. Food and Drug Administration. FDA clears first over-the-counter continuous glucose monitor (press announcement), 2024. FDA
24. Healio. FDA grants 510(k) clearance for OTC sale of needle-free CGM, October 2, 2026. Healio
25. TIME. Biolinq Shine, The Best Inventions of 2026 (availability: by prescription, over the counter expected early 2027). TIME